What Are Peptides?

A peptide is a short chain of amino acids linked together by peptide bonds — the same fundamental building blocks your body uses to build proteins, enzymes, and hormones. The distinction between a peptide and a protein is largely one of size: peptides typically contain fewer than 50 amino acids, while proteins are longer, more structurally complex chains.

Think of amino acids as individual letters. Peptides are short words — 2 to 50 characters. Proteins are novels. Both are written in the same alphabet, but the length determines the function and the complexity of how the molecule folds, binds, and behaves inside a biological system.

The Peptide Bond

What holds amino acids together in a peptide is the peptide bond — a covalent chemical bond formed between the carboxyl group (–COOH) of one amino acid and the amine group (–NH₂) of the next, releasing a water molecule in the process. This reaction is called condensation, and it's repeated for every link in the chain.

The directionality of this chain matters: peptides have a defined start (the N-terminus, where the free amine group sits) and a defined end (the C-terminus, the free carboxyl end). This direction affects how the molecule behaves — and why slight structural modifications can produce dramatically different biological effects.

Size Classifications

Researchers classify peptides by chain length, and the terminology has specific meanings in a lab context:

Natural vs. Synthetic

Peptides occur naturally in every living organism. But the molecules studied in modern laboratory research are often synthetic peptides — sequences either identical to naturally occurring compounds or deliberately modified to enhance stability, bioavailability, or receptor selectivity.

The ability to synthesize precise peptide sequences on demand — which only became practical in the 1960s — is what transformed peptide chemistry from an academic curiosity into one of the most productive areas of biomedical research. That story begins in the early twentieth century.

Peptide science didn't emerge from a single eureka moment. It was assembled over decades by chemists, physiologists, and biochemists working in parallel — often in different countries, often unaware of each other's progress. The key figures of this era laid down the vocabulary and the tools that the entire field would later build on.

The Chemistry Catches Up to the Biology

By 1900, biologists already knew that living organisms produced chemical messengers — substances that could travel through the bloodstream and produce effects in distant tissues. They didn't know what these substances were made of. The chemistry to answer that question was only beginning to mature.

Why This Period Mattered

The Discovery Era established three things that still define peptide science today: (1) the structural model — amino acids linked by peptide bonds; (2) the signaling paradigm — small molecules communicating between tissues; and (3) the therapeutic possibility — that these molecules, if you could obtain or replicate them, could correct deficiencies in living organisms.

What researchers lacked was a reliable method to produce them. Isolating insulin from thousands of animal pancreases was viable as a medical intervention. It was not viable as a research tool. That would require a completely different approach — one that wouldn't emerge until the early 1950s.

For the first half of the twentieth century, researchers could study peptides but couldn't reliably build them. Isolation from biological sources was laborious, impure, and species-dependent. To study a peptide's function, you needed massive quantities of the right tissue. That changed in 1953 with the first complete chemical synthesis of a biologically active peptide.

Vincent du Vigneaud and Oxytocin

In 1953, American biochemist Vincent du Vigneaud and his team at Cornell University Medical College completed the chemical synthesis of oxytocin — a 9-amino-acid peptide — and demonstrated that their synthetic version produced identical biological effects to the natural hormone.

This was a watershed moment. For the first time, a researcher could build a biologically active peptide in a lab, test it, modify it, and compare modified versions to the original. Du Vigneaud was awarded the Nobel Prize in Chemistry in 1955 — just two years after the synthesis — a recognition of how significant the scientific community understood the achievement to be.

Merrifield's Solid-Phase Synthesis

The synthesis of oxytocin, while revolutionary, was still an enormously labor-intensive process. Each amino acid addition required careful purification before the next step could proceed — a process that was slow, wasteful, and difficult to scale.

In 1963, Bruce Merrifield at Rockefeller University published a paper describing a fundamentally new method he called solid-phase peptide synthesis (SPPS). Rather than building the peptide in solution, Merrifield anchored the growing chain to a solid resin bead — allowing each step to be completed, washed, and advanced without intermediate purification.

What SPPS Changed

Before SPPS, synthesizing a 20-amino-acid peptide might take a trained chemist a year and produce milligram quantities of impure product. After SPPS, the same peptide could be assembled in days, with automated washing and coupling cycles. The implications were enormous:

Researchers could now make analogs — modified versions of natural peptides with a single amino acid changed — and compare them systematically. They could build peptides that had never existed in nature. They could study how structural changes altered receptor binding, stability, or potency. The science moved from descriptive to experimental almost overnight.

By the early 1980s, the tools existed to build virtually any peptide sequence. The challenge shifted from how to make them to which ones to make. This era is defined by systematic receptor mapping, structure-activity relationship (SAR) studies, and the discovery of peptide classes that would later become foundational to modern research.

Growth Hormone Secretagogues

One of the most productive research areas of the 1980s and 1990s was the study of growth hormone (GH) regulation. Researchers knew that the pituitary released GH in pulses, but the receptor-level mechanism was unclear. In 1977, Cyril Bowers at Tulane University began exploring synthetic enkephalin analogs and discovered that some of them unexpectedly stimulated GH release.

This led to the development of the Growth Hormone Releasing Peptide (GHRP) family — synthetic oligopeptides that bind a receptor distinct from the endogenous growth hormone-releasing hormone (GHRH) pathway. GHRP-6, the first well-characterized member of this family, became a standard tool in neuroendocrinology research throughout the 1990s.

The Recombinant Revolution

The 1980s brought a second major production method alongside SPPS: recombinant DNA technology. By inserting the gene for a peptide into bacteria or yeast, researchers could produce large quantities of longer peptides and proteins that were difficult to assemble chemically. Recombinant human growth hormone, approved by the FDA in 1985, was the first major product of this approach.

SPPS and recombinant production became complementary: SPPS for peptides under ~50 residues, recombinant for larger proteins. Together, they gave researchers access to essentially the entire natural peptide library, plus anything they could design.

Structure-Activity Relationships and Analog Programs

The defining methodology of this era was the SAR study — systematically replacing individual amino acids in a known sequence and measuring how each change affected activity. Thousands of analogs of ACTH, substance P, enkephalins, and other signaling peptides were synthesized and tested, building detailed maps of which residues were critical for receptor binding and which could be modified to alter stability or selectivity.

Peptide Therapeutics Mature

By 2010, peptide-based therapeutics had become one of the most active drug development categories. Over 60 peptide drugs had been approved worldwide, generating over $13 billion in annual revenue. More importantly for research, the commercial incentive to develop better synthesis, formulation, and stability methods produced enormous advances in the underlying tools available to academic and industrial researchers alike.

Modern peptide research is defined less by new synthesis methods and more by the accumulating depth of evidence around specific compounds. Where 1990s research was largely exploratory — what does this peptide do? — research from 2010 onward has increasingly focused on mechanism: why it does it, and what variables affect the magnitude of the effect.

BPC-157: The Cytoprotective Fragment

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — 15 amino acids — derived from a protein found in human gastric juice. First characterized in the 1990s by Dr. Predrag Sikiric at the University of Zagreb, BPC-157 has accumulated one of the largest bodies of animal research of any synthetic peptide currently studied.

The research interest stems from a consistent pattern across independent studies: the compound appears to interact with multiple repair and regeneration pathways simultaneously, with activity documented in tendon, ligament, muscle, gut, nerve, and vascular tissue in rodent models. The mechanism appears to involve upregulation of nitric oxide synthesis and interaction with the VEGF (vascular endothelial growth factor) pathway.

Tesamorelin: GHRH Analog

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus that increases stability. It's one of the few research peptides to have advanced through full clinical trials, resulting in FDA approval (as Egrifta) for HIV-associated lipodystrophy.

For the research community, tesamorelin represents a well-characterized model for studying the GHRH receptor pathway. Its clinical approval means an unusually complete dataset is available on pharmacokinetics, efficacy, and safety profile in human subjects — making it one of the best-documented peptides for comparative research purposes.

Selank and Semax: Peptide Nootropics

Originally developed at the Russian Institute of Molecular Genetics in the 1990s, Selank and Semax represent a category of research peptides based on fragments of endogenous neuropeptides. Selank is derived from the immunomodulatory peptide tuftsin; Semax is derived from ACTH(4-7).

Both compounds have been approved in Russia for human clinical use, producing an unusually rich clinical dataset by Western research standards. The neurotrophic and anxiolytic effects observed in multiple independent studies have sustained active research programs examining their interaction with BDNF signaling and GABAergic transmission.

Peptides do not enter cells the way small molecule drugs often do. Most research peptides act at the cell surface, binding to specific receptor proteins embedded in the plasma membrane. The binding event triggers a conformational change in the receptor that initiates intracellular signaling — the cell's internal communication network that ultimately changes what genes are expressed and what proteins are produced.

Receptor Selectivity

One of the most important concepts in peptide research is receptor selectivity. A peptide that binds tightly to only one receptor type is highly selective; one that binds many receptor types is promiscuous. High selectivity is generally desirable for research purposes because it allows cleaner attribution of observed effects — if a compound only binds receptor X, then effects observed after administration are likely mediated through receptor X.

Many natural peptide hormones evolved to be highly selective. Growth hormone-releasing hormone (GHRH) binds specifically to the GHRH receptor (GHRHR) on pituitary somatotroph cells, triggering GH release with minimal off-target activity. Synthetic analogs like Tesamorelin are designed to preserve this selectivity while adding metabolic stability.

G Protein-Coupled Receptors (GPCRs)

The majority of peptide hormones and their synthetic analogs signal through G protein-coupled receptors (GPCRs) — a family of seven-transmembrane proteins that represent the largest class of drug targets in medicine. When a peptide binds a GPCR, it triggers the exchange of GDP for GTP on an associated G protein, initiating a cascade that can increase intracellular cAMP, activate protein kinase A, or mobilize calcium from intracellular stores depending on the G protein subtype involved.

The GLP-1 receptor, target of semaglutide and related compounds, is a GPCR. So is the growth hormone secretagogue receptor (GHSR), target of ghrelin and synthetic secretagogues like ipamorelin. Understanding which G protein a receptor couples to is critical for predicting a peptide's downstream effects.

Receptor Tyrosine Kinases (RTKs)

Some peptide growth factors signal through receptor tyrosine kinases (RTKs) rather than GPCRs. IGF-1 and insulin, for example, bind transmembrane receptors that phosphorylate tyrosine residues on themselves and downstream proteins upon ligand binding, activating the PI3K/Akt and MAPK/ERK pathways. These pathways regulate cell proliferation, survival, and differentiation — explaining the growth-promoting effects observed in IGF-1 receptor agonist research.

Direct Intracellular Mechanisms

A smaller number of research peptides are thought to act through intracellular mechanisms rather than surface receptors. BPC-157, for instance, appears to interact with the nitric oxide system and VEGF signaling through mechanisms that are not fully characterized. Some researchers have proposed direct effects on gene transcription, though the evidence for this remains preliminary. The incomplete mechanistic picture for BPC-157 is both why it generates research interest and why interpreting its study results requires care.

Binding Affinity and IC50/EC50

Two numbers appear repeatedly in peptide pharmacology literature: IC50 (inhibitory concentration 50%) and EC50 (effective concentration 50%). IC50 refers to the concentration required to inhibit a target by 50% — commonly used for antagonists or competitive binding assays. EC50 refers to the concentration that produces 50% of the maximum possible response — used for agonists.

Lower values indicate higher potency. A peptide with an EC50 of 0.1 nM is ten times more potent at its receptor than one with an EC50 of 1 nM. These values are determined in cell-based assays under controlled conditions and may not directly translate to in vivo potency, where distribution, metabolism, and tissue accessibility all modify the effective concentration at the receptor.

Agonists, Partial Agonists, and Antagonists

A peptide that binds a receptor and activates it fully is a full agonist. One that activates it partially — producing a submaximal response regardless of concentration — is a partial agonist. One that binds without activating, blocking the endogenous ligand from binding, is an antagonist. One that binds and produces the opposite of the receptor's normal activity is an inverse agonist.

Many synthetic peptide analogs are partial agonists — they activate their target receptor but with less efficacy than the natural peptide hormone. This can be intentional: partial agonism at some receptors produces effects that full agonism would overshoot or cause desensitization.

Biased Agonism

A more recently understood concept is biased agonism (also called functional selectivity). The same receptor can couple to multiple downstream pathways depending on which ligand is bound. Two agonists at the same receptor can have very different effects if one preferentially activates G-protein signaling while the other preferentially activates β-arrestin signaling. This has significant implications for interpreting study results and for designing compounds with improved therapeutic windows.

GLP-1 receptor agonist research has produced particularly clear examples of biased agonism, where small structural modifications to the peptide shift the balance between G-protein and β-arrestin coupling, changing both the metabolic effects and the side effect profile of the compound.

Signal Transduction Cascades

Once a receptor is activated, the signal travels through a cascade of intracellular proteins, each activating the next. Common cascades activated by peptide hormone receptors include:

• cAMP/PKA pathway: Activated by Gs-coupled GPCRs (GHRHR, GLP-1R). cAMP activates PKA, which phosphorylates CREB and other transcription factors, leading to gene expression changes including GH synthesis and insulin secretion.
• PLC/IP3/DAG pathway: Activated by Gq-coupled GPCRs. Releases intracellular calcium and activates PKC, influencing muscle contraction, secretion, and cell proliferation.
• PI3K/Akt/mTOR pathway: Activated by RTKs (IGF-1R, InsR). Central to anabolic signaling, protein synthesis, and cell survival. mTOR is the major regulator of muscle protein synthesis.
• MAPK/ERK pathway: Activated by multiple receptor types. Regulates cell proliferation, differentiation, and survival. Chronically elevated ERK signaling is a feature of many tumor cells.

What Is Biological Half-Life?

Biological half-life (t½) is the time it takes for the concentration of a compound in a biological system to fall to half its initial value. For peptides administered systemically, this is primarily governed by two processes: enzymatic degradation (proteolysis) and renal clearance.

Most endogenous peptides have very short half-lives — minutes to hours — because they're designed for tight temporal regulation. Growth hormone-releasing hormone has a half-life of approximately 7 minutes in circulation. Insulin: ~5 minutes. GLP-1 (native): ~2 minutes. These short half-lives are biologically appropriate for hormones that need rapid on/off control, but they present challenges for research applications requiring sustained exposure.

Enzymatic Degradation

The primary route of peptide degradation in biological systems is proteolysis — cleavage by proteases. These enzymes are present in blood (serum proteases), on cell surfaces, and in intracellular compartments. Different proteases cleave at different amino acid sequences; knowing which proteases are active in a given tissue helps predict where a peptide will be most rapidly degraded.

Several common degradation points affect research peptides:

• N-terminal degradation: Aminopeptidases cleave from the N-terminus. Protected by adding N-terminal modifications (acetylation, DAC groups, trans-3-hexenoic acid in Tesamorelin).
• C-terminal degradation: Carboxypeptidases cleave from the C-terminus. Protected by C-terminal amidation, which also affects receptor binding affinity in some peptides.
• DPP-IV cleavage: Dipeptidyl peptidase-4 rapidly cleaves the first two amino acids from GLP-1 and related peptides. Semaglutide and other stable GLP-1 analogs incorporate structural modifications specifically to resist DPP-IV cleavage.

Lyophilization and Storage Stability

In research settings, peptides are most commonly supplied as lyophilized powders — freeze-dried forms that remove water while preserving molecular structure. This is distinct from biological half-life (which applies to active compound in a biological system) and concerns storage stability: how long the peptide remains chemically intact sitting in a vial.

The primary degradation pathways for stored peptides are hydrolysis (water-mediated cleavage of peptide bonds) and oxidation (particularly of methionine, cysteine, and tryptophan residues). Removing water through lyophilization dramatically slows hydrolysis. Storing under inert atmosphere and away from light slows oxidation. The combination of lyophilization + cold storage (−20°C) + dark, anhydrous conditions can extend peptide stability for years.

Once reconstituted with bacteriostatic water, peptides are vulnerable again. BAC water extends usability by inhibiting microbial growth, but chemical degradation continues at a slow rate even at refrigerator temperatures. Most reconstituted peptide solutions should be used within 28–30 days at 2–8°C.

Half-Life Engineering in Synthetic Analogs

Modern peptide drug design frequently involves deliberate modification to extend half-life. Strategies include fatty acid conjugation (semaglutide's C18 fatty acid chain binds albumin, extending its half-life from 2 minutes to ~7 days), PEGylation (attaching polyethylene glycol chains to slow renal clearance), and structural cyclization (forming internal disulfide or lactam bonds that resist proteolysis).

For researchers, understanding these modifications is critical for interpreting pharmacokinetic data. A longer half-life means less frequent dosing to maintain target concentrations, but also slower washout when ending an experiment. The Half-Life Reference Chart in the research library compares t½ values across common research peptides with notes on the structural features responsible for each compound's stability profile.